Corcept Therapeutics Incorporated (NASDAQ:CORT) said on Thursday that it presented results from its Phase 2 DAZALS study of ...

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...

Brainstorm tapped Minaris to manufacture NurOwn for its upcoming Phase 3b clinical trial testing the treatment for ALS.

US commercial-stage drugmaker Corcept Therapeutics (Nasdaq: CORT) has presented results from its DAZALS study of dazucorilant ...

Nothing is clicking for a Rangers offense that is so bad, it has made its great pitching staff nearly irrelevant. | Opinion ...

Corcept Therapeutics has tried to cast its recent phase 2 amyotrophic lateral sclerosis (ALS) failure in a more flattering ...

Analysts at Truist Securities called the mid-stage data a "mixed bag," also flagging gastrointestinal adverse events. However ...

UC Irvine researchers conducted a study to better understand the molecular basis of amyotrophic lateral sclerosis (ALS), a ...

Corcept Therapeutics' dazucorilant failed the primary ALS trial goal but showed improved survival outcomes and a safe profile ...

It’s been nearly a year since Charlottesville lost one of its most respected pediatricians. At 65, he was diagnosed with a ...

The Everylife Foundation for Rare Diseases is offering a new scholarship for U.S. students from the ALS community facing ...

Dr. Simrit Parmar, an associate professor in the College of Medicine at Texas A&M University and founder of the ...